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Abstract
Purpose of Review This review aims to present current information on genes underlying severe obesity, with the main emphasis
on the three genes LEP, LEPR and MC4R.
Recent Findings There is a substantial amount of evidence that variants in at least ten different genes are the cause of severe
monogenic obesity. The majority of these are involved in the leptin-melanocortin signalling pathway. Due to the frequency of
some of the identified variants, it is clear that monogenic variants also make a significant contribution to common obesity.
Summary The artificial distinction between rare monogenic obesity and common polygenic obesity is now obsolete with the
identification of MC4R variants of strong effect in the general population.
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Introduction
Obesity is both very common, with a prevalence of 12%
globally, and accompanied by high rates of serious, life-
threatening, complications such as type 2 diabetes, cardio-
vascular disease and cancer [1]. Its underlying causes are
complex and have proven relatively difficult to elucidate
[2•]. A person with a body mass index (BMI) of 30 kg/
m2, or more, is defined as obese, and severe obesity has
been strictly defined as a BMI within the range of 35–
39.9 kg/m2 [3]. However, severe obesity is frequently de-
fined with the broader meaning of having a BMI of great-
er than 35 kg/m2, that is it includes obesity classes II, III
and IV (see Table 1). BMI has been used to assess obesity
rates in populations in relation to health with some con-
siderable success [4], and prevalence is high in many
countries, such as the USA and UK (see Table 1). The
economic cost of obesity to national health systems and
the wider society is a considerable burden on wealthy
economies [5], particularly severe obesity [6] and an
alarming prospect for such emerging large economies as
China where obesity rates are rising fast [7].
While it has been evident for many years that there is a
strong genetic component affecting obesity, with twin studies
providing reproducible heritability values as high as 0.77
across different regions of the world and at different ages
[8•], there has been relatively little investigation of severe
obesity specifically. This is almost certainly due to the consid-
erable overlap between rare monogenic obesity and common
polygenic obesity at this part of the distribution of BMI within
the population. However, at least one study has attempted to
investigate genetic effects in severe obesity [9]. This used a
definition of morbid obesity of 45.5 kg over the ideal weight
of an individual, something that would actually place many
people in the category of severely obese based on current
definitions (see Table 1). Family members of probands were
found to be eight times more likely to be severely obese than
the general population. They also demonstrated that families
with at least one severely obese parent were 2.6 times more
likely to have one or more severely obese adult offspring
compared to the general population. This suggested that ge-
netic effects were important in this sub-group of the obese but
could not eliminate the effects of shared environment.
With a role for genetics well established in obesity, the
focus for this review is on severe obesity as a distinct disease
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with a specific genetic cause rather than syndromic or com-
mon polygenic obesity. The overlap of rare monogenic dis-
ease with common obesity will also be discussed.
Monogenic Severe Obesity
This review will concentrate on the original obesity gene,
leptin (LEP) and its receptor (LEPR), together with a gene that
has been identified as having variants of strong effect giving
rise to both monogenic obesity and obesity in the general
population, the melanocortin-4 receptor (MC4R). Additional
selected genes reported to be associated with severe obesity
are listed in Table 2, to provide a flavour of the current state of
the art without attempting to be comprehensive.
Early work with mouse models implicated leptin and its
cognate receptor as implicated in monogenic obesity [21,
22]. Rare human cases where leptin, or the leptin receptor, is
entirely ablated have subsequently been reported and uniformly
exhibit severe obesity [23–25].
Leptin
Leptin is a hormone secreted by adipose tissue [26] and leptin
levels are directly related to adiposity in humans [27]. It is
constitutively expressed, and in conditions of prolonged calo-
ric deficit, fat stores and leptin production will decrease [28].
It is a cytokine (or adipokine) essential for regulation of ener-
gy balance through feeding behaviour and energy expenditure
[21]. Leptin is anorexigenic and seems likely to be our main
adiposity indicator and signal of nutritional status: plasma
levels are highly correlated to adipocyte number and fat mass
[29]. Leptin levels are also strongly correlated with insulin
resistance independently of fat volume; thus, hyperleptinaemia
can be considered an independent factor in obesity (see [30]
for review).
Leptin signals by binding to the leptin receptor (a type I
cytokine receptor) in the arcuate nucleus of the hypothalamus,
reducing the desire to eat and stimulating thermogenesis [31].
Leptin signalling is via the JAK-STAT pathway [32–34].
Circulating leptin binds to the soluble form of the leptin
receptor, sOB-R [35], and activates Janus kinase (JAK2),
which then phosphorylates three tyrosine residues in LEPR,
which then induces the phosphorylation of STAT transcription
factors STAT5 and STAT3 (see [36] for review). This provides
the metabolic link between leptin levels and the many down-
stream energy homeostatic pathways it regulates, which in-
clude growth, caloric expenditure and glycaemic control. In
addition to behavioural control regarding food intake and se-
cretion of adrenal corticosteroids, circulating leptin induces its
effects via LepRb [37], the long form of its receptor, which is
expressed specifically in areas of the brain with a role in feed-
ing and energy expenditure [38]. In normal weight individ-
uals, if leptin is decreased due to reduction in white adipose
tissue, such as during prolonged starvation, this induces
orexigenic signalling, which results in decreased energy use
and disruption of glucose homeostasis (see [38] for review).
The mechanism by which this pathway is dysregulated is
complex and has been demonstrated to include factors that
have varying levels of influence such as feedback inhibition,
inflammatory responses, gliosis and endoplasmic reticulum
stress [39]. Circulating leptin levels are increased in obese
humans and also in animal models, but the essential feedback
mechanism that promotes reduction in feeding behaviour and
increased energy expenditure fails [40]. Interestingly, leptin
receptors continue to respond to the increased leptin [41]. It
appears that an obese end point is reached despite increased
leptin-leptin receptor signalling but that continuous high
levels of leptin receptor signalling induce leptin resistance
and “caps” the amplitude of the signal [39, 42].
There are currently only eight different mutations reported
in the LEP gene that are thought to cause severe obesity (see
[13] for review). Recent studies, including exome sequencing,
have increased the numbers of known variants but LEP mu-
tations remain very rare (see Table 2). Allelic variation has
been extensively studied with the view that these may confer
greater propensity to obesity. For example, family-based as-
sociation analysis of a large consanguineous Tunisian family
identified the functional variants (H1328084 and A19G) in the
5′ UTR of LEP. These variants have been associated with
plasma leptin level as a quantitative trait and are thus impli-
cated in affecting plasma leptin levels [43].
Many candidate gene and genome-wide association studies
(GWAS) have been carried out where LEP and LEPR poly-
morphisms have been investigated for their role in measures
of adiposity, obesity and its sequelae [13, 44–48]. There is a
relatively small amount of literature positively implicating
LEP polymorphisms in this role and the relationship is depen-
dent on ethnicity and age of subject [44, 49]. LEP G2548A
Table 1 Body mass index (BMI) ranges, corresponding descriptions
and rates of each category in the USA and UK for adults of both sexes
in the latest year for which data was available*
BMI range
(kg/m2)
Description USA
%
UK
%
< 18.5 Underweight 2.4 5.1
18.5–24.9 Normal weight 35.7 33.9
25–29.9 Overweight 32.2 38.3
30–34.9 Obesity class I (obese) 33.9 22.70
35–39.9 Obesity class II (severely obese)
> 40 Obesity class III (morbidly obese
> 50 Obesity class III (super obese)
Table created using data from WHO Global Health Observatory data;
http://www.who.int/gho/ncd/risk_factors/overweight/en/
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has been associated with obesity and serum leptin levels in
Turkish subjects [50] and a study that reports a synergistic
effect of LEP and LEPR polymorphisms on BMI, in a Han
Chinese population [51]. In a Pakistani population, this poly-
morphism has also been shown to be associated with obesity
in female children < 18 years old. In addition, G-2548A poly-
morphism showed association with BMI, fasting blood glu-
cose and serum leptin levels in male and female children [52].
It is clear that ascertainment of traits has a profound impact
on identification of positive associations. LEP polymorphisms
G2548A in a recent meta-analysis involving 1372 obese indi-
viduals (BMI > 30 kg/m2) and 1616 controls concluded that
there was no association with LEP [49]. However, three stud-
ies show a positive association with severe obesity in
Taiwanese aboriginals and Caucasians [53–55].
Leptin Receptor
The leptin receptor gene, LEPR at 1p31, encodes a single
membrane spanning receptor of the class I cytokine receptor
family [22]. There are six leptin receptor or ObR isoforms
produced by alternative splicing [56, 57]. With different iso-
forms being expressed in different tissues [58], these include
one long form (LEPR or ObRb), four short forms (ObRa,
ObRc, ObRd and ObRf, with unique C-termini) and one sol-
uble form (ObRe). LEPR, the long form, which is the isoform
truncated in obese mice (ob/ob) and known to be important in
energy and feeding control, contains three highly conserved
tyrosine residues (Y985, Y1077, Y1138) required for efficient
leptin signalling [21, 38, 59]. Its major site of expression is the
arcuate nucleus neurones, which are known to have a role in
energy homeostasis and are reported to be responsive to leptin
signalling (see [60] for review). Many of these neurones also
express pro-opiomelanocortin (POMC) in response to excita-
tion by leptin, and via central nervous system (CNS)
melanocortin receptors (MCRs), play a key role in negatively
moderating feeding behaviour and increasing energy expen-
diture [38, 61].
Truncation of LEPR has been shown to cause morbid
monogenic obesity and severe hyperphagia in mice (db/db)
and humans [37, 62–64]. Genome scans and association stud-
ies have linked LEPR to measures of adiposity including en-
ergy expenditure in: a population with elevated obesity levels,
fat mass, skinfold and fat-free mass; BMI trends in childhood;
and leptin levels, body composition, insulin dysregulation and
glucose metabolism. The leptin receptor also has a role in the
hypothalamic-pituitary-gonadal axis, thus influencing onset of
puberty [65].
Numerous coding single-nucleotide variants (SNVs) have
been identified in the LEPR gene including: Lys109Arg
(rs1137100), which lies in the cytokine homology domain
(CK); Gln223Arg (rs8179183) in the loop region of the CK
domain; and the Lys656Asn (rs8179183), in the fibronectin
type III (F3) domain [66, 67]. These domains are common to
all the isoforms.
Table 2 Selected genes with variants contributing to severe monogenic obesity with recent reviews
Gene
symbol
Full name Location Obesity Associated traits Recent reviews
ADCY3 Adenylate cyclase 3 2p23.3 Severe-early
onset
Type 2 diabetes Tian et al. 2018 [10]
BDNF Brain-derived
neurotrophic
factor
11p14.1 Severe-early
onset
Hyperphagia, severe obesity, hyperactivity and impaired
cognitive function.
Han et al. 2016 [11]
KSR2 Kinase suppressor of
ras 2
12q24.22-q24.23 Severe Hyperphagia (in childhood), insulin resistance and
reduced basal metabolic rate.
Frodyma et al. 2017 [12]
LEP Leptin 7q32.1 Severe, early
onset
Hyperphagia, hypogonadotropic hypogonadism. Some
evidence for neuroendocrine/metabolic and immune
dysfunction
Wasim et al 2016; Yeo
2017 [13, 14]
LEPR Leptin receptor 1p31.3 Severe, early
onset
Hyperphagia, hypogonadotropic hypogonadism. Some
evidence for neuroendocrine/metabolic and immune
dysfunction
Wasim et al 2016; Yeo
2017 [13, 14]
MC4R Melanocortin 4
receptor
18q21.32 Severe, early
onset
Increased linear growth and final height, fasting
hyperinsulinemia and incompletely suppressed growth
hormone secretion.
Krashes et al 2016; Yeo
2017; Novoselova et
al 2018 [14–16]
PCSK1 Proprotein
convertase
subtilisin/kexin
type 1
5q15 Severe –
occurring
in
childhood
Hyperphagia, impaired glucose homeostasis, decreased
linear growth, hypothyroidism, hypocortisolism and
hypogonadotropic hypogonadism
Ramos-Molina et al
2016; Stijnen et al
2016 [17, 18]
POMC Proopiomelanocortin 2p23.3 Severe, from
the first
months
Adrenocorticotropic hormone (ACTH) deficiency, red
hair and pale skin
Anderson et al 2016;
Rubinstein and Low
2017 [19, 20]
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The association of these variants with common severe obe-
sity and obesity-related phenotypes has been reinforced
through evidence generated by a multitude of candidate gene
studies [44, 48]. Understanding common complex obesity
through identification of genes mutated in rare severe obesity
must be carefully interpreted in terms of the direction of the
effects. In addition, care must be taken in selecting a sample
group that is not phenotypically heterogeneous, i.e. over-
weight, obese and morbidly obese pooled, for example.
Indeed, extreme phenotyping is a refinement of this practice
and has had some notable successes in identifying genes im-
plicated in quantitative traits, including obesity and obstruc-
tive sleep apnoea, for which obesity and leptin levels are sig-
nificant risk factors [68, 69]. With complex disease, subtle
phenotypic heterogeneity may mask underlying contributions
from variants of modest effect, especially since the precise
phenotypic effect of the variant is unknown and may be dif-
ferent in different ethnic groups. Nevertheless, there is over-
whelming evidence that common variants in LEPR are asso-
ciated with measures of adiposity. This seems unlikely to be a
direct effect but is likely to be due to subtle variations in
functionality whose effect is amplified in downstream targets
[39].
Melanocortin-4 Receptor
The MC4R protein is a membrane-bound G-protein-coupled
receptor found in several brain regions, including the
paraventricular nucleus (PVN) in the hypothalamus (see [70]
for review). Stimulation of LEPR on POMC neurons causes
them to release α-melanocyte-stimulating hormone (α-MSH)
(see [38] for review), which binds to the MC4R protein. This
results in the exocytosis of brain-derived neurotrophic factor
(BDNF) and neurotrophic tyrosine kinase receptor 2
(NTRK2) (see [71] for review), which are both anorexigenic
signals. It should be noted that very recent studies have report-
ed that leptin only directly regulates Agouti-related protein
(AGRP) neurons [72, 73]. With many functional relationships
regulating the orexigenic-anorexigenic signal balance, it is not
surprising that variation in the genes involved in the
melanocortin-leptin pathway can give rise to severe obesity
[70, 74].
MC4R Gene Sequence Variation
MC4R-deficient patients are affected by hyperphagia and,
consequently, a higher caloric intake [75, 76].MC4R variation
was recognised relatively early as a monogenic cause of se-
vere obesity, accounting for as much as 6% of people with
early onset obesity [77]. Most people affected are heterozy-
gous, demonstrating autosomal dominant inheritance [78, 79].
Homozygous cases have also been reported and they display a
more severe form of obesity [77, 80].
Currently, there are 376 SNVs and 189 copy number var-
iants reported in the MC4R gene region. A total of 182 of the
SNVs are missense, 10 are nonsense and 12 are frameshift
variants. Of these SNVs, 69 are predicted pathogenic, or likely
pathogenic. Only two SNVs have been identified with a minor
allele frequency (MAF) > 1% in the 1000 genomes (1000G)
or the ExAC reference population datasets: namely
rs34114122 (1000G MAF = 6.0%, ExAC MAF = not avail-
able) and rs2229616 (1000G MAF = 1.6% and ExAC MAF
1.7%) (data from NCBI Variation Viewer, 27th June 2018)
[81, 82].
Clinical Phenotype
Obese patients with mutant MC4R genes are very similar to
other obese patients with no identifiedMC4R mutation. They
share a similar mean BMI with other obese patients, as well as
maximum BMI reached during adult life and minimal BMI
reached during caloric restriction [80]. No difference in food
intake, incidence of diabetes and glucose intolerance has been
observed between the two groups. Fasting glucose, triglycer-
ide levels and mean leptin levels were also the same.
However, when looking at childhood obesity, MC4R mutant
carriers have a higher percentage body fat composition of 67.0
vs 45.5% in other obese children.
When comparing BMI standard deviation, individuals with
heterozygous mutations had a score of 2.79 ± 1.61 (mean ±
SD) while homozygotes for MC4R mutations had a score of
4.81 ± 1.63 (mean ± SD). During the first 5 years of life, mu-
tant MC4R carriers show a higher standard deviation for
height, a higher body fat percentage of 42.9% compared to
15–25% normal body fat percentage range and a higher fat-
free mass than homozygous wild-type subjects, suggesting
that MC4R deficiency is characterised by increased fat and
lean mass. Therefore, children with MC4R deficiency were
taller and more obese than their peers. The study also proved
that these children have a higher bone mineral density which
corresponds with previous studies [77].
As these patients grow older, hyperphagia decreases and
their metabolic rate becomes similar to healthy individuals.
Adult MC4R mutation carriers do not have an increased risk
of diabetes and the hyperinsulinemia seen in children de-
creases to normal levels after the age of 10. These individuals
also show normal endocrine function. There is no strong evi-
dence that binge eating is a phenotype of MC4R deficiency as
originally suggested [83–85].
Bariatric surgery is currently the only successful option in
treating obesity, but when bariatric surgery has been per-
formed on homozygous mutant MC4R patients, it had no im-
pact on long-term weight loss [86, 87].
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GWAS for Severe Obesity
The identification of genes underlying common obesity
has been predominantly focused on the phenotype of
BMI. This was due to three reasons: the presence of this
phenotype in many cohorts recruited for other reasons, the
clear relationship with definitions of obesity in popula-
tions and the fact it is a simple to measure quantitative
trait. However, the first association reported with common
obesity originated from a type 2 diabetes study. Variants
in the FTO gene were associated with type 2 diabetes at
genome-wide significance, but this association was not
significant when BMI was taken into account [88]. This
has led to very many GWAS and meta-analyses for BMI
conducted with hundreds of thousands of subjects (e.g.
[89, 90]). The main problem with the focus on BMI is
that the associations detected are to variants that contrib-
ute to the distribution of BMI within a cohort, rather than
the variants that associate with obesity specifically.
There are fewer GWAS that have investigated associa-
tions with severe obesity and those that have are relatively
small and under-powered, with the exception of the most
recent meta-analysis (see below). One of the earliest
GWAS used both adults with morbid obesity and obese
children, arguing that early-onset obesity was likely to be
predominantly genetic. Associations were reported with
the two genes already identified in the general population,
FTO and MC4R, but associations were also reported with
SNVs in the NPC1 gene and near to the MAF and PTER
genes [91]. Recently, it has been reported that rare vari-
ants in the NPC1 gene are enriched in young severely
obese Chinese subjects and that heterozygosity for these
variants also leads to increased BMI compared to age-
matched controls [92]. The variant near to the MAF gene
is midway between the MAF gene and the MAFTRR gene
(MAF transcriptional regulator RNA), a long non-coding
RNA that regulates MAF expression, suggesting that the
association may be with a causal variant that affects tran-
scription of MAF, or another, as yet undiscovered, target
of MAFTRR. The variant reported near to the PTER gene
is in fact closer to several non-coding RNA genes, includ-
ing the long non-coding RNA RP11-461K13.1 and the U6
small nuclear pseudogene RNU6-1075P, again suggesting
the possibility that the association is in fact to a variant
that affects expression of gene targets of these non-coding
RNAs.
A stepwise analytical approach was used in another
study where an initial small GWAS was carried out in
164 morbidly obese and 163 always-lean adults, followed
by taking the positive associations in two further stages of
700 SNVs in 460/247 cases and controls and then 23
SNVs in 4214 obese versus 5417 lean or population-
based controls [93]. The initial GWAS demonstrated
nominal association (p < 0.05) with variants in brain-
derived neurotrophic factor (BDNF) and MC4R, but not
in FTO. Variants in the genes KCNMA1 (potassium
calcium-activated channel subfamily M alpha 1) and
BDNF were reported to be associated with obesity at
genome-wide significance. Notably, the SNV in
KCNMA1, rs2116830, was not associated with BMI in
the population-based controls and the KCNMA1 transcript
was over-expressed in adipose tissue in obese adults. This
suggests the possibility that KCNMA1 is purely associated
with obesity rather than BMI, but given the relatively
small numbers of controls, this result might simply reflect
a lack of statistical power.
A GWAS for severe early-onset obesity in a total of 2480
children reported four loci, namely leptin receptor (LEPR),
protein kinase C eta (PRKCH), phosphofurin acidic cluster
sorting protein 1 (PACS1) and rhabdomyosarcoma 2-
associated transcript (RMST) [94]. Association of the previ-
ously reported 43-kb deletion near to NEGR1was also report-
ed but this was determined to be due to linkage disequilibrium
with an 8-kb deletion the other side of the NEGR1 locus.
Pathway analysis was reported to suggest enrichment of g
protein coupled receptors involved in the neuronal regulation
of energy homeostasis. It is notable that similar to the earlier
GWAS, association was seen to a locus containing a long non-
coding RNA, RMST, suggesting that non-coding RNA loci
deserve more attention as containing possible obesity-
causing variants.
More recently, a very large meta-analysis of the data avail-
able to the GIANT consortium generated seven new loci as-
sociated with BMI, two of which were associated with class II
severe obesity [95••]. The study analysed 15,334 cases and
97,858 controls for the specific class II analysis and identified
two novel loci, as well as previously reported associations
withMC4R and KCNMA1. The new loci were HS6ST3 (hep-
aran sulfate 6-O-sulfotransferase 3) and ZZZ3 (zinc finger ZZ-
type containing 3). Neither of the new genes identified have
any reported functional relationship with obesity or BMI.
Study sizes continue to grow in order to increase statistical
power, in response to the challenge of detecting loci of small
effect, withMAF values < 0.05. Recently, in a study analysing
data from > 700,000 subjects on an exome array, a further
eight novel gene loci have been associated with BMI, impli-
cating novel candidate pathways involved in obesity and re-
lated phenotypes [96•]. The strength of this study is that the
cohort is over twice the size of most other GWAS studies to
date. Interestingly, these data suggest that MC4R and KSR2
were identified as having a role in common, complex obesity.
These genes have previously been identified in much smaller
studies, where subjects’ obese phenotype was severe and early
onset [69, 89, 97, 98].
TwoMCR4 SNVs were used in the analysis that were array-
wide significant at p < 2 × 10−7: a missense mutation
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(Asp37Val, rs12447325) and a nonsense mutation (Tyr35Ter,
rs13447324), both with a MAF of 0.01%, thus present in 1/
5000 subjects. The Tyr35Ter mutation which leads to MC4R
deficiency and hyperphagia [75, 76, 78] results in approximate-
ly 7 kg of extra weight for a person 1.7 m in height and gave the
largest effect size in the whole study. Interestingly, MC4R
Ille251Leu (rs52820871) is reported in the literature as
ameliorating obesity [99]. The KSR2 variant identified in this
study (Arg554Gln, rs56214831) increases body weight by 0.
74 kg/allele and is known to be associated with hyperphagia-
induced obesity, low basal metabolic rate and insulin resistance
in mice and humans [69, 100–102].
Effect sizes of rare variants are generally higher than com-
mon SNVs positively identified in GWAS and this is the case
forMC4R and KSR2, but penetrance is low and the 14 SNVs,
identified in this large exome array study [96•], combined
represent < 0.1% of BMI variation. Of the new loci identified,
EPAC1 (RAPGEF3) is known to play a role in energy homeo-
stasis, diabetes and obesity propensity and regulates insulin
and leptin signalling [103–105]. Interestingly, knockdown
models of adipose specific epac were lethal in Drosophila,
which was not the case for the eight other newly identified
loci investigated [96•].
Conclusions
Over 20 years since the report of the first gene involved in
obesity, we now have a far better understanding of the genetics
of severe obesity. We have identified a range of genes respon-
sible for severe monogenic obesity and we now know that
some of these are frequent enough to be significant causes of
obesity in the general population. The boundary between rare
monogenic obesity and common polygenic obesity is now
becoming blurred. This is not unexpected but it has not really
become evident until recently with the technological advances
in genotyping and sequencing that now allow us to character-
ise all variants across the whole genome in large numbers of
cases and controls.
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